Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss)

12 Months Ended

Jun. 30, 2021

Notes to Financial Statements

Comprehensive Income (Loss) Note [Text Block]

Note 8. Supplemental Equity and Accumulated Other Comprehensive Income (loss): 

Supplemental Equity

The Company has declared cash dividends per share of $1.28 in each of the full fiscal years ended  June 30, 2021, June 30, 2020, and June 30, 2019. During the years ended June 30, 2021 and June 30, 2020, the Company repurchased 120,000 shares at an average share price of $359.81 and 279,381 shares at an average share price of $179.37, respectively. The Company's accounting policy is to record the portion of share repurchases in excess of the par value entirely in retained earnings. During fiscal year 2021, 2020 and 2019, the amounts within the Consolidated Statements of Shareholders' Equity for the surrender and retirement of stock to exercise options due to net settlement stock options exercises were not material.

Accumulated Other Comprehensive Income (loss) 

Changes in accumulated other comprehensive income (loss) attributable to Bio-Techne, net of tax, are summarized as follows (in thousands):

	Unrealized Gains (Losses) on Available- for-Sale Investments			Foreign Currency Translation Adjustments			Unrealized Gains (Losses) on Derivatives Instruments			Total
Balance June 30, 2018	$	24,682		$	(69,496	)	$	-		$	(44,814	)
Cumulative effect adjustment for adoption for ASU 2018-02		2,371			-			-			2,371
Cumulative effect adjustment for adoption for ASU 2016-01		(27,053	)		-			-			(27,053	)
Other comprehensive income (loss) before reclassifications		-			(4,487	)		(9,537	)		(14,024	)
Balance June 30, 2019	$	-		$	(73,983	)	$	(9,537	)	$	(83,521	)
Other comprehensive income (loss) before reclassifications		-			(9,963	)		(7,179	)		(17,142	)
Reclassification from loss on derivatives to interest expense, net of taxes		-			-			3,464			3,464
Balance June 30, 2020	$	-		$	(83,946	)	$	(13,253	)	$	(97,199	)
Other comprehensive income (loss) before reclassifications(2)		-			32,848			100			32,948
Reclassification from loss on derivatives to interest expense, net of taxes(1)		-			-			6,960			6,960
Balance June 30, 2021	$	-		$	(51,098	)	$	(6,193	)	$	(57,291	)

(1) Gains (losses) on the interest swap will be reclassified into interest expense as payments on the derivative agreement are made. The Company reclassified $8,598 to interest expense and $512 to non-operating income relating to variable interest payments that were probable not to occur as further discussed in Note 5 for the fiscal year ended June 30, 2021. The Company also recorded a related tax benefit of $2,150 during fiscal 2021. The Company had deferred tax benefits of $1,908 and $4,058 included in the accumulated other comprehensive income loss as of June 30, 2021 and June 30, 2020, respectively.

(2) Other comprehensive income related to foreign currency translation adjustments in the table above includes the amount attributable to Bio-Techne and excludes the $103 attributable to the non-controlling interest in Eminence.